ICOMETRIX NV

Their core work

icometrix is a Belgian medical AI company that develops automated brain and lung imaging analysis software. Their core technology uses machine learning and deep learning to extract quantitative biomarkers from MRI and CT scans, supporting clinical decision-making in neurology and pulmonology. They provide AI-powered diagnostic and prognostic tools used in clinical trials and hospital settings, turning complex medical images into actionable clinical reports.

What they specialise in

How they've shifted over time

icometrix began as a specialist contributor in brain imaging training networks and neurological disease modelling (2015-2018), participating in projects like ChildBrain and EuroPOND that focused on foundational neuroimaging research. From 2019 onward, their work shifted toward applied clinical AI — deploying machine learning for diagnostics and prognosis in real clinical settings, including their COVID-19 lung CT tool and MS immunotherapy trials. This evolution reflects a clear trajectory from research-stage imaging science toward market-ready AI diagnostic products.

icometrix is moving from being a research partner in imaging consortia to becoming a product-driven AI diagnostics company, now coordinating its own clinical AI projects.

How they like to work

icometrix predominantly joins as a specialist partner (7 of 8 projects), bringing their imaging AI expertise into larger research consortia. They stepped into a coordinator role only once — for icovid, their largest-funded project — suggesting growing confidence in leading clinical AI initiatives. With 88 unique partners across 16 countries, they maintain a broad European network rather than relying on a small circle of repeat collaborators.

icometrix has collaborated with 88 unique partners across 16 countries, indicating a well-connected position in European medical imaging and neuroscience research. Their Leuven base places them in one of Europe's strongest biomedical research hubs, with connections radiating across the continent.

What sets them apart

icometrix occupies a rare position as an SME that bridges the gap between academic neuroimaging research and clinical AI products. Unlike pure research groups, they bring commercial software (icolung, icobrain) into EU consortia, meaning partners get access to validated, deployable AI tools — not just prototypes. Their dual capability in brain MRI and lung CT analysis makes them unusually versatile for medical imaging projects.

Highlights from their portfolio

• icovid
  Their only coordinated project and largest funding (EUR 850K) — a rapid-response AI tool for COVID-19 chest CT analysis, showing their ability to pivot technology to urgent clinical needs.
• EuroPOND
  Data-driven neurological disease progression modelling with EUR 639K funding — represents their deepest investment in predictive neurology AI.
• RESTORE
  Directly targets multiple sclerosis treatment through immunotherapy, placing icometrix's imaging biomarkers at the intersection of neurology and immunology.